There shall be twelve directors who, in addition to five officers, shall constitute the Board of Directors. There shall be balanced representation among academia, government and industry and voluntary health organizations on the Board of Directors. The Board of Directors shall manage the property and affairs of the Organization subject to these Bylaws.

OFFICERS
	President Thomas P. Sutula, M.D., Ph.D. University of Wisconsin - Madison		President Elect TBD		Secretary TBD
	Treasurer O’Neill D’Cruz, M.D., MBA, FAAN OD Consulting and Neurological Services, PLLC		Immediate Past President Martha Morrell, M.D. NeuroPace, Inc
BOARD OF DIRECTORS
	Enrique J. Carrazana, M.D. Mariunus Pharma		Amy S. Chappell, M.D., Eliem Therapeutics and Carnot Biosciences		Gail Farfel, Ph.D. Zogenyx, Inc.
	Stewart A. Factor, D.O. Emory University School of Medicine		Toby Ferguson, M.D., Ph.D. Biogen Idec, Inc		Lindsey Lair, M.D. Janssen
	Bennett L, Lavenstein, M.D. Co-Chair Children’s Hospital Medical Center		John R. Richert, M.D. Richert Partners		Steven Schachter, M.D. CIMIT/Harvard Medical School
	David Shoup The Curry Rockefeller Group
EX-OFFICIO BOARD MEMBERS
	Development Committee Chair Martha Morrell, M.D. NeuroPace, Inc		Neurotherapeutics® Editor-in-Chief M. Maral Mouradian, M.D. Rutgers University		Program Committee Chair C. Anthony Altar, Ph.D. Verge Genomics
	NIH Training in Neurotherapeutics Course Liaison Barbara Slusher, Ph.D., MAS John Hopkins Brain Science Institute		Federal Liaison Amir Tamiz, Ph.D. NIH, NINDS, OTR
	Communications Terrie Blalock, RN, MS TBlalock Consulting
EXECUTIVE STAFF
	Executive Director Jessica Keenan Smith ASENT